PMOS (previously PCOS): what the new name means

Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome (PCOS), is a hormonal and metabolic condition. The World Health Organization estimates that it affects 10% to 13% of women of reproductive age. Older medical records and health services may continue to use PCOS during the transition to the new name.

How PMOS is assessed

There is no single test. After other possible causes are excluded, adults are generally assessed for three features: irregular or absent ovulation, clinical or blood-test signs of higher androgen levels, and polycystic ovaries on ultrasound. The international guideline also allows an anti-Mullerian hormone test to be used instead of ultrasound in some adults. At least two of the three features are required. An ultrasound appearance alone does not establish PMOS.

Assessment is different in adolescents. Current guidance requires both ovulatory dysfunction and signs of higher androgen levels; ultrasound and anti-Mullerian hormone are not recommended for diagnosis in this age group. PMOS can be associated with metabolic, fertility and mental-health concerns, but symptoms and risks vary between individuals.

Health beyond periods and fertility

PMOS is an endocrine and metabolic condition, not only a period or fertility condition. The international guideline includes glucose status, cardiovascular risk factors and symptoms of obstructive sleep apnoea in assessment. These risks are not determined by body size alone. A clinician can explain which checks are relevant now and when they may need repeating.

Mental health belongs in PMOS care

Depression and anxiety symptoms, body-image distress and disordered eating are more common among people with PMOS. The guideline recommends mental-health screening in parts of PMOS care. These experiences do not diagnose the condition, but they deserve assessment and support in their own right.

Why the name changed

An international consensus process adopted PMOS on 12 May 2026. The new name is intended to describe the condition's broader endocrine and metabolic features without implying that ovarian cysts are required. PCOS remains useful as a search term while records, guidelines and services update their wording.

The terminology update did not create a new diagnosis or replace the 2023 international guideline. Its recommendations remain in place. During the transition, a clinician, pharmacy or insurer may still use PCOS, PMOS or both terms.

What happens after assessment

A GP or gynaecologist may discuss cycle symptoms, blood tests, metabolic health and, for adults, whether imaging is useful. Management should follow your symptoms and priorities and may include support for cycles, metabolic health, skin or hair symptoms, mental health, or fertility. Ask which diagnostic criteria are being used and what other causes have been excluded.

Support should not depend on weight loss

Eating patterns and physical activity can support general health, metabolic health and quality of life even when weight does not change. The guideline also recognises that weight stigma can harm care. A useful plan focuses on health outcomes, access and personal circumstances rather than blame.